National Bank of Canada
KYMR icon

National Bank of Canada’s Kymera Therapeutics KYMR Stock Holding History

National Bank of Canada’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-600
Closed – – 2836
2022
Q3 		$0 Sell
600
-150
-20% -$3.95K ﹤0.01% 2801
2022
Q2 		$15K Buy
+750
New +$17.5K ﹤0.01% 2152

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

National Bank of Canada's KYMR Position: Q4 2022 in Review

National Bank of Canada sold out of Kymera Therapeutics (KYMR) in Q4 2022, closing a stake of 600 shares.

National Bank of Canada first reported a position in KYMR in Q2 2022 and held it in 2 quarters. The position peaked at $15K in Q2 2022. 121 funds tracked by Wall St. Rank hold KYMR as of Q4 2022.

  • National Bank of Canada reported no remaining Kymera Therapeutics position as of Q4 2022 after selling out during the quarter.
  • National Bank of Canada sold 600 Kymera Therapeutics shares in Q4 2022.
  • National Bank of Canada first reported a position in Kymera Therapeutics in Q2 2022 and held it in 2 quarters.
  • National Bank of Canada's Kymera Therapeutics position peaked at $15K in Q2 2022.
  • 121 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2022.

Based on National Bank of Canada's 13F filing for Q4 2022, filed 24 Jan 2023.